Skip to main content

Table 2 Statistical comparison of DCV PK parameters when administered with and without DTG

From: No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

Plasma DCV PK parameter

Geometric mean (CV%)

Geometric least-squares mean ratio (90 % CI)

DCV alone (treatment B)

(N = 12)

DCV + DTG (treatment C)

(N = 12)

DCV + DTG vs DCV alone

Cmax (μg/mL)

1.19 (42.6)

1.22 (42.2)

1.03 (0.843–1.25)

AUC0-τ (hr · μg/mL)

11.4 (47.9)

11.2 (41.6)

0.978 (0.831–1.15)

Cτ (μg/mL)

0.166 (69.3)

0.176 (53.8)

1.06 (0.876–1.29)

CL/F (L/hr)

5.25 (47.9)

5.36 (41.6)

1.02 (0.868–1.203)

t1/2 (hr)

8.58 (23.2)

8.42 (29.4)

0.982 (0.814–1.18)

  1. Abbreviations: AUC 0-τ area under the concentration-time curve over the dosing interval, C τ concentration at the end of the dosing interval, CI confidence interval, CL/F apparent clearance following oral dosing, C max maximum observed concentration, CV% coefficient of variation, DCV daclatasvir, DTG dolutegravir, PK pharmacokinetic, t 1/2 terminal phase half-life
  2. Treatment B = DCV 60 mg once daily; treatment C = DTG 50 mg once daily plus DCV 60 mg once daily